Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655719 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone in Thyroid Cancers
A Phase 2 study of Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 4
- Study locations
NCT01655719 is a Phase 2 study of Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene that has completed, run by University of Michigan. The registered enrollment target is 1 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT01655719, a Phase 2 study of Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 4
- Study locations
Study Summary
Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimental.
Conditions Studied
Interventions
- DRUG Pioglitazone
Study Locations (4)
Colorado
- University of Colorado - Aurora
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Est. Completion | 2017-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01655719
The ClinicalTrials.gov registry entry for NCT01655719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene appearing as the primary indexed condition, and to 1 intervention - of which Pioglitazone is the first listed.
NCT01655719 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01655719 about?
NCT01655719 is a clinical study titled "Pioglitazone in Thyroid Cancers". Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimen...
What is the current status of trial NCT01655719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2012-04. Estimated completion is 2017-03-31.
What conditions does trial NCT01655719 study?
This clinical trial studies the following conditions: Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene.
What interventions are being tested in trial NCT01655719?
The interventions under investigation include: Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT01655719?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01655719 being conducted?
This trial has 4 study locations across Colorado, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.